{"id":833455,"date":"2026-09-02T16:21:02","date_gmt":"2026-09-02T16:21:02","guid":{"rendered":"https:\/\/www.abnewswire.com\/pressreleases\/?p=833455"},"modified":"2026-09-02T16:21:02","modified_gmt":"2026-09-02T16:21:02","slug":"short-bowel-syndrome-market-is-projected-to-witness-significant-growth-by-2036-owing-to-the-rising-burden-of-gastrointestinal-conditions-and-expansion-of-glp2-analog-therapies-delveinsight","status":"publish","type":"post","link":"https:\/\/www.abnewswire.com\/pressreleases\/short-bowel-syndrome-market-is-projected-to-witness-significant-growth-by-2036-owing-to-the-rising-burden-of-gastrointestinal-conditions-and-expansion-of-glp2-analog-therapies-delveinsight_833455.html","title":{"rendered":"Short Bowel Syndrome Market is Projected to Witness Significant Growth by 2036 Owing to the Rising Burden of Gastrointestinal Conditions and Expansion of GLP-2 Analog Therapies | DelveInsight"},"content":{"rendered":"<div style=\"float:right;  width:250px; padding:8px 10px 10px 10px;\"><a href=\"https:\/\/www.abnewswire.com\/upload\/2026\/09\/1788340492.jpg\" style=\"border:none !important;\" target=\"_blank\" rel=\"nofollow\" ><img loading=\"lazy\" decoding=\"async\" class=\"alignnone size-medium wp-image-29\" title=\"Short Bowel Syndrome Market is Projected to Witness Significant Growth by 2036 Owing to the Rising Burden of Gastrointestinal Conditions and Expansion of GLP-2 Analog Therapies | DelveInsight\" src=\"https:\/\/www.abnewswire.com\/upload\/2026\/09\/1788340492.jpg\" alt=\"Short Bowel Syndrome Market is Projected to Witness Significant Growth by 2036 Owing to the Rising Burden of Gastrointestinal Conditions and Expansion of GLP-2 Analog Therapies | DelveInsight\" width=\"225\" height=\"118\" \/><\/a><\/div>\n<p style=\"text-align: justify;\"><strong>(Albany, New York) &#8211; 2nd Sep 2026 &#8211;<\/strong>&nbsp;The market dynamics for Short Bowel Syndrome (SBS) are witnessing steady growth driven by increasing cases of conditions such as Crohn&rsquo;s disease, necrotizing enterocolitis, and gastrointestinal surgeries, particularly among neonates and the elderly, along with the growing need to reduce dependence on parenteral nutrition. Additionally, the expansion of GLP-2 analog therapies, including GATTEX\/REVESTIVE (teduglutide), Apraglutide, Glepaglutide (ZP1848), and Sonefpeglutide (HM15912), is expected to further propel the Short Bowel Syndrome market during the forecast period.<\/p>\n<p style=\"text-align: justify;\">DelveInsight, a leading market research firm, announces the release of its latest report, &#8220;DelveInsight&#8217;s Short Bowel Syndrome Market Insights, Epidemiology and Market Forecast &ndash; 2036.&#8221; This comprehensive report provides an in-depth understanding of Short Bowel Syndrome, including historical and forecasted epidemiology, market trends, treatment scenarios, patient burden, and competitive landscape across the United States, EU4 (Germany, Spain, Italy, France), the United Kingdom, and Japan.<\/p>\n<p style=\"text-align: justify;\">Key Takeaways from the Short Bowel Syndrome Market<\/p>\n<ul style=\"text-align: justify;\">\n<li>\n<p>The market size for Short Bowel Syndrome in the leading markets is expected to grow significantly by 2036.<\/p>\n<\/li>\n<li>\n<p>The 7MM Short Bowel Syndrome market was approximately USD 2,500 million in 2025 and is projected to increase to nearly USD 4,100 million by 2036, reflecting a 5% CAGR during 2026&ndash;2036.<\/p>\n<\/li>\n<li>\n<p>According to DelveInsight&#8217;s estimates, there were approximately 14,500 diagnosed prevalent cases of Short Bowel Syndrome in the United States in 2025, with the number projected to increase by 2036.<\/p>\n<\/li>\n<li>\n<p>In 2025, the United States had the highest number of diagnosed prevalent cases of Short Bowel Syndrome among the 7MM.<\/p>\n<\/li>\n<li>\n<p>Females accounted for more than 60% of diagnosed SBS cases in the United States in 2025, while males represented more than 30% of cases.<\/p>\n<\/li>\n<li>\n<p>In 2025, adults represented approximately 85% of diagnosed prevalent SBS cases in the United States, driven by rising surgical volumes, an aging population, and improved post-surgical survival.<\/p>\n<\/li>\n<li>\n<p>Parenteral Support held the highest market share among SBS therapies in 2025 and is projected to maintain its dominant position through 2036.<\/p>\n<\/li>\n<li>\n<p>GATTEX\/REVESTIVE (teduglutide), developed by Takeda, remains an important marketed therapy for reducing dependence on parenteral nutrition in patients with SBS.<\/p>\n<\/li>\n<li>\n<p>Leading Short Bowel Syndrome companies, including Takeda, Ironwood Pharmaceuticals (VectivBio), Zealand Pharma, Hanmi Pharmaceutical, Napo Therapeutics, and others, are actively developing innovative therapies expected to transform the SBS treatment landscape over the coming years.<\/p>\n<\/li>\n<li>\n<p>Promising Short Bowel Syndrome therapies in clinical development include Apraglutide, Glepaglutide (ZP1848), Sonefpeglutide (HM15912), and MYTESI (crofelemer).<\/p>\n<\/li>\n<\/ul>\n<p style=\"text-align: justify;\">Keen to know more about the market? Request our sample page at<a rel=\"nofollow\" href=\"https:\/\/www.delveinsight.com\/sample-request\/short-bowel-syndrome-market?utm_source=abnewswire&amp;utm_medium=pressrelease&amp;utm_campaign=kspr\">https:\/\/www.delveinsight.com\/sample-request\/short-bowel-syndrome-market<\/a><\/p>\n<p style=\"text-align: justify;\">Key Factors Driving the Short Bowel Syndrome MarketIncreasing Cases of Gastrointestinal Conditions and Surgeries<\/p>\n<p style=\"text-align: justify;\">Increasing cases of Crohn&rsquo;s disease, necrotizing enterocolitis, and gastrointestinal surgeries, particularly among neonates and the elderly, are contributing to the growing burden of Short Bowel Syndrome. Major bowel resection is a primary cause of SBS, creating continued demand for nutritional support and therapeutic interventions.<\/p>\n<p style=\"text-align: justify;\">Growing Need to Reduce Parenteral Nutrition Dependence<\/p>\n<p style=\"text-align: justify;\">Total parenteral nutrition remains a cornerstone of SBS management, particularly in severe cases. However, long-term dependence on parenteral support is associated with substantial costs, complications, and quality-of-life challenges. The growing focus on achieving enteral independence and intestinal autonomy is therefore driving demand for therapies that can reduce dependence on parenteral nutrition.<\/p>\n<p style=\"text-align: justify;\">Expansion of GLP-2 Analog Therapies<\/p>\n<p style=\"text-align: justify;\">The development of GLP-2 analogs is significantly expanding therapeutic opportunities in SBS. Emerging therapies such as Apraglutide, Glepaglutide, and Sonefpeglutide are being developed to improve intestinal adaptation and absorption while reducing or eliminating the need for parenteral support.<\/p>\n<p style=\"text-align: justify;\">Growing Focus on Advanced and Disease-Modifying Therapies<\/p>\n<p style=\"text-align: justify;\">The SBS treatment landscape is shifting from reliance on supportive care toward advanced therapies designed to promote intestinal adaptation and nutritional independence. The declining use of older growth hormone therapies and continued innovation in biologics are expected to support market growth during the forecast period.<\/p>\n<p style=\"text-align: justify;\">Short Bowel Syndrome Competitive Landscape<\/p>\n<p style=\"text-align: justify;\">The Short Bowel Syndrome treatment landscape remains centered on parenteral support, dietary modifications, enteral feeding, oral rehydration, medications, and management of complications. In severe cases, surgical procedures and intestinal transplantation may be considered. Parenteral support currently accounts for the largest share of the market because of its widespread use and comparatively lower cost.<\/p>\n<p style=\"text-align: justify;\">GATTEX\/REVESTIVE (teduglutide), developed by Takeda, is an important marketed therapy for SBS. Teduglutide is a recombinant analogue of human GLP-2 that promotes intestinal rehabilitation and is designed to reduce dependence on parenteral nutrition in adults with SBS.<\/p>\n<p style=\"text-align: justify;\">The emerging pipeline is increasingly focused on next-generation GLP-2 therapies. Apraglutide, developed by Ironwood Pharmaceuticals (VectivBio), is an investigational long-acting synthetic GLP-2 analog being developed for SBS with intestinal failure. Glepaglutide (ZP1848), developed by Zealand Pharma, is another long-acting GLP-2 analog designed for subcutaneous administration and intended to reduce or eliminate dependence on parenteral support.<\/p>\n<p style=\"text-align: justify;\">Other emerging approaches include Sonefpeglutide (HM15912) from Hanmi Pharmaceutical, a long-acting GLP-2 analog, and MYTESI (crofelemer) from Napo Therapeutics, an oral therapy being investigated for SBS with intestinal failure without chronic intestinal failure. These emerging therapies are expected to further reshape the SBS treatment landscape over the forecast period.<\/p>\n<p style=\"text-align: justify;\">Discover more about therapies set to grab major Short Bowel Syndrome market share @<a rel=\"nofollow\" href=\"https:\/\/www.delveinsight.com\/sample-request\/short-bowel-syndrome-market?utm_source=abnewswire&amp;utm_medium=pressrelease&amp;utm_campaign=kspr\"> Short Bowel Syndrome Treatment Landscape<\/a><\/p>\n<p style=\"text-align: justify;\">Recent Developments in the Short Bowel Syndrome Market<\/p>\n<ul style=\"text-align: justify;\">\n<li>\n<p>In April 2025, Ironwood Pharmaceuticals announced that, following discussions with the US FDA, a confirmatory Phase III trial would be needed to seek approval of apraglutide for patients with SBS-IF who are dependent on parenteral support.<\/p>\n<\/li>\n<li>\n<p>In April 2025, Ironwood Pharmaceuticals presented real-world data at the 2025 Digestive Disease Week (DDW) meeting focused on the adoption and utilization of recently approved ICD-10 codes among SBS patients dependent on parenteral support.<\/p>\n<\/li>\n<li>\n<p>In August 2025, Zealand Pharma reported completion of its Type A meeting with the US FDA regarding the design of the EASE-5 Phase III trial for glepaglutide and anticipated initiation of the trial in H2 2025.<\/p>\n<\/li>\n<li>\n<p>In August 2025, Zealand Pharma anticipated potential approval of glepaglutide for the treatment of adult patients with SBS in Europe in H1 2026, while also engaging in partnership discussions for future commercialization.<\/p>\n<\/li>\n<\/ul>\n<p style=\"text-align: justify;\">What is Short Bowel Syndrome?<\/p>\n<p style=\"text-align: justify;\">Short Bowel Syndrome (SBS) is a complex condition caused by the loss or dysfunction of portions of the small and\/or large intestine, resulting in reduced absorption of nutrients, fluids, and electrolytes. Patients may experience severe diarrhea, dehydration, malnutrition, and weight loss, and severe cases can become life-threatening.<\/p>\n<p style=\"text-align: justify;\">In adults, the normal small bowel length ranges from approximately 275&ndash;850 cm, while SBS is typically defined as having less than 180&ndash;200 cm of remaining small intestine, often requiring nutritional support. Most cases arise following major bowel resection, with prognosis largely depending on the patient&#8217;s age and underlying disease.<\/p>\n<p style=\"text-align: justify;\">Diagnosis is based on medical history, physical examination, blood work, fecal fat analysis, and imaging. Additional procedures such as endoscopy or liver biopsy may be used to evaluate complications. Treatment is individualized and focuses on maintaining nutrition, promoting intestinal adaptation, and managing complications through total parenteral nutrition (TPN), enteral feeding, dietary modifications, medications, and, in severe cases, surgery or intestinal transplantation.<\/p>\n<p style=\"text-align: justify;\">Short Bowel Syndrome Epidemiology Segmentation<\/p>\n<p style=\"text-align: justify;\">The Short Bowel Syndrome epidemiology section provides insights into the historical and current SBS patient pool and forecasted trends across the seven major markets. The Short Bowel Syndrome market report provides epidemiological analysis for the study period 2022&ndash;2036, segmented into:<\/p>\n<ul style=\"text-align: justify;\">\n<li>\n<p>Total Diagnosed Prevalent Cases of Short Bowel Syndrome in the 7MM<\/p>\n<\/li>\n<li>\n<p>Gender-specific Diagnosed Prevalent Cases of Short Bowel Syndrome in the 7MM<\/p>\n<\/li>\n<li>\n<p>Age-specific Diagnosed Prevalent Cases of Short Bowel Syndrome in the 7MM<\/p>\n<\/li>\n<li>\n<p>Etiology-specific Diagnosed Prevalent Cases of Short Bowel Syndrome in the 7MM<\/p>\n<\/li>\n<li>\n<p>Patient Burden Assessment<\/p>\n<\/li>\n<\/ul>\n<p style=\"text-align: justify;\">Scope of the Short Bowel Syndrome Market Report<\/p>\n<ul style=\"text-align: justify;\">\n<li>\n<p>Therapeutic Assessment: Current marketed and emerging therapies for Short Bowel Syndrome<\/p>\n<\/li>\n<li>\n<p>Short Bowel Syndrome Market Dynamics: Key market forecast assumptions, pricing trends, therapy uptake, and market outlook<\/p>\n<\/li>\n<li>\n<p>Key Companies: Takeda, Ironwood Pharmaceuticals (VectivBio), Zealand Pharma, Hanmi Pharmaceutical, Napo Therapeutics, and others<\/p>\n<\/li>\n<li>\n<p>Key Therapies: GATTEX\/REVESTIVE (teduglutide), Apraglutide, Glepaglutide (ZP1848), Sonefpeglutide (HM15912), MYTESI (crofelemer), and others<\/p>\n<\/li>\n<li>\n<p>Competitive Intelligence Analysis: SWOT Analysis and Conjoint Analysis<\/p>\n<\/li>\n<li>\n<p>Unmet Needs, KOL&#8217;s Views, Analyst&#8217;s Views, Short Bowel Syndrome Market Access and Reimbursement<\/p>\n<\/li>\n<\/ul>\n<p style=\"text-align: justify;\">To know more about Short Bowel Syndrome companies working in the treatment market, visit @<a rel=\"nofollow\" href=\"https:\/\/www.delveinsight.com\/sample-request\/short-bowel-syndrome-market?utm_source=abnewswire&amp;utm_medium=pressrelease&amp;utm_campaign=kspr\"> Short Bowel Syndrome Clinical Trials and Therapeutic Assessment<\/a><\/p>\n<p style=\"text-align: justify;\">Table of Contents<\/p>\n<ul style=\"text-align: justify;\">\n<li>\n<p>Short Bowel Syndrome Market Report Introduction<\/p>\n<\/li>\n<li>\n<p>Executive Summary of Short Bowel Syndrome<\/p>\n<\/li>\n<li>\n<p>Key Events<\/p>\n<\/li>\n<li>\n<p>Epidemiology and Market Methodology<\/p>\n<\/li>\n<li>\n<p>Short Bowel Syndrome Market Overview at a Glance<\/p>\n<\/li>\n<li>\n<p>Clinical Landscape<\/p>\n<\/li>\n<li>\n<p>Short Bowel Syndrome Background and Overview<\/p>\n<\/li>\n<li>\n<p>Etiology<\/p>\n<\/li>\n<li>\n<p>Symptoms<\/p>\n<\/li>\n<li>\n<p>Pathophysiology<\/p>\n<\/li>\n<li>\n<p>Consequences of Short Bowel Syndrome<\/p>\n<\/li>\n<li>\n<p>Complications of Short Bowel Syndrome<\/p>\n<\/li>\n<li>\n<p>Diagnosis<\/p>\n<\/li>\n<li>\n<p>Differential Diagnosis<\/p>\n<\/li>\n<li>\n<p>Treatment of Short Bowel Syndrome<\/p>\n<\/li>\n<li>\n<p>Treatment Guidelines of Short Bowel Syndrome<\/p>\n<\/li>\n<li>\n<p>Epidemiology and Patient Population of Short Bowel Syndrome<\/p>\n<\/li>\n<li>\n<p>Country-Specific Patient Population of Short Bowel Syndrome<\/p>\n<\/li>\n<li>\n<p>Patient Journey of Short Bowel Syndrome<\/p>\n<\/li>\n<li>\n<p>Marketed Therapy<\/p>\n<\/li>\n<li>\n<p>Short Bowel Syndrome Emerging Therapies<\/p>\n<\/li>\n<li>\n<p>Short Bowel Syndrome Market Outlook<\/p>\n<\/li>\n<li>\n<p>Country-Wise Short Bowel Syndrome Market Analysis (2022&ndash;2036)<\/p>\n<\/li>\n<li>\n<p>Short Bowel Syndrome Market Access and Reimbursement of Therapies<\/p>\n<\/li>\n<li>\n<p>Short Bowel Syndrome Market Drivers<\/p>\n<\/li>\n<li>\n<p>Short Bowel Syndrome Market Barriers<\/p>\n<\/li>\n<li>\n<p>Short Bowel Syndrome Appendix<\/p>\n<\/li>\n<li>\n<p>Short Bowel Syndrome Report Methodology<\/p>\n<\/li>\n<li>\n<p>DelveInsight Capabilities<\/p>\n<\/li>\n<li>\n<p>Disclaimer<\/p>\n<\/li>\n<li>\n<p>About DelveInsight<\/p>\n<\/li>\n<\/ul>\n<p style=\"text-align: justify;\">About DelveInsight<\/p>\n<p style=\"text-align: justify;\">DelveInsight is a leading market research and consulting firm specializing in the life sciences and healthcare industries. Founded in 2014, the company provides comprehensive market intelligence, epidemiology, and insights across pharmaceuticals, biotechnology, medical devices, and emerging therapies. DelveInsight helps healthcare organizations make informed strategic decisions through data-driven research and industry expertise.<\/p>\n<p><span style='font-size:18px !important;'>Media Contact<\/span><br \/><strong>Company Name:<\/strong> <a href=\"https:\/\/www.abnewswire.com\/companyname\/delveinsight.com_56431.html\" rel=\"nofollow\">DelveInsight Business Research LLP<\/a><br \/><strong>Contact Person:<\/strong> Kirti Sharma<br \/><strong>Email:<\/strong> <a href=\"https:\/\/www.abnewswire.com\/email_contact_us.php?pr=short-bowel-syndrome-market-is-projected-to-witness-significant-growth-by-2036-owing-to-the-rising-burden-of-gastrointestinal-conditions-and-expansion-of-glp2-analog-therapies-delveinsight\" rel=\"nofollow\">Send Email<\/a><br \/><strong>Phone:<\/strong> 9193216187<br \/><strong>Address:<\/strong>304 S. Jones Blvd #2432  <br \/><strong>City:<\/strong> Las Vegas<br \/><strong>State:<\/strong> Nevada<br \/><strong>Country:<\/strong> United States<br \/><strong>Website:<\/strong> <a href=\"https:\/\/www.delveinsight.com\/\" target=\"_blank\" rel=\"nofollow\">https:\/\/www.delveinsight.com\/<\/a><\/p>\n<p><img decoding=\"async\" src=\"https:\/\/www.abnewswire.com\/press_stat.php?pr=short-bowel-syndrome-market-is-projected-to-witness-significant-growth-by-2036-owing-to-the-rising-burden-of-gastrointestinal-conditions-and-expansion-of-glp2-analog-therapies-delveinsight\" alt=\"\" width=\"1px\" height=\"1px\" \/><\/p>\n","protected":false},"excerpt":{"rendered":"<p>(Albany, New York) &#8211; 2nd Sep 2026 &#8211;&nbsp;The market dynamics for Short Bowel Syndrome (SBS) are witnessing steady growth driven by increasing cases of conditions such as Crohn&rsquo;s disease, necrotizing enterocolitis, and gastrointestinal surgeries, particularly among neonates and the elderly, &hellip; <a href=\"https:\/\/www.abnewswire.com\/pressreleases\/short-bowel-syndrome-market-is-projected-to-witness-significant-growth-by-2036-owing-to-the-rising-burden-of-gastrointestinal-conditions-and-expansion-of-glp2-analog-therapies-delveinsight_833455.html\">Continue reading <span class=\"meta-nav\">&rarr;<\/span><\/a><\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[435,405,406,420,404],"tags":[],"class_list":["post-833455","post","type-post","status-publish","format-standard","hentry","category-Europe","category-Health-Medicine","category-Pharmaceuticals-Biotech","category-Science","category-US"],"_links":{"self":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/posts\/833455","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/comments?post=833455"}],"version-history":[{"count":0,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/posts\/833455\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/media?parent=833455"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/categories?post=833455"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/tags?post=833455"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}